Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Real-World Effectiveness and Safety of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) for Hereditary Angioedema: An Observational Study in China

NCT06346899 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06346899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06346899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Real-World Effectiveness and Safety of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) for Hereditary Angioedema: An Observational Study in China
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
July 20, 2024
Completion date
July 31, 2025
Enrollment
115 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)